Journal of cataract and refractive surgery · 2026
Phakic presbyopic intraocular lenses: systematic review.
СтатьяСистематический обзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
González-Lugo Javier H, Zhang Hao, Alió Jorge L, Ghanem Marcielle, Medalle Ronald Steven, Alió Del Barrio Jorge L
Аннотация
TOPIC: Presbyopia affects nearly 2 billion individuals worldwide and remains a major unmet challenge in refractive surgery. This systematic review evaluated the visual, refractive, and safety outcomes of phakic intraocular lenses (pIOLs) specifically designed for presbyopia correction, including multifocal and extended depth-of-focus (EDOF) models. Eligible participants were presbyopic adults undergoing unilateral or bilateral pIOL implantation. Comparisons across optical designs and fixation types were examined in relation to visual performance and adverse events.
CLINICAL RELEVANCE: Current presbyopia-correcting options, including corneal procedures and refractive lens exchange, may compromise accommodation or optical quality. Phakic presbyopic IOLs aim to restore full-range vision while preserving the crystalline lens, potentially offering a safer, reversible alternative.
METHODS: This review followed PRISMA guidelines and was prospectively registered in PROSPERO (CRD420251138158). Comprehensive searches were conducted in MEDLINE, PubMed, EMBASE, Registers, and the Cochrane Library through July 2025. Eligible studies included clinical trials and observational studies reporting visual, refractive, safety, or patient-reported outcomes of presbyopia-correcting pIOLs. Risk of bias was assessed using the Cochrane and ROBINS-I tools.
RESULTS: 6 studies (354 eyes) were included. Contemporary pIOL designs; EVO Viva Implantable Collamelar Lens, trifocal Implantable Phakic Contact Lens, and ArtiPlus achieved at least 75% of eyes within ±0.50 diopter of target refraction, and 80% to 90% of patients attained functional spectacle independence. Glare and halos were commonly reported but generally mild. No sight-threatening adverse events occurred during short-term follow-up.
CONCLUSIONS: Early evidence suggests favorable short-term safety and functional outcomes for presbyopia-correcting pIOLs while preserving the crystalline lens and residual accommodative function. However, evidence remains limited by short follow-up, small sample sizes, and industry sponsorship. Independent, long-term studies are required to establish their definitive role in refractive surgery.
REGISTRATION: PROSPERO CRD420251138158.
CLINICAL RELEVANCE: Current presbyopia-correcting options, including corneal procedures and refractive lens exchange, may compromise accommodation or optical quality. Phakic presbyopic IOLs aim to restore full-range vision while preserving the crystalline lens, potentially offering a safer, reversible alternative.
METHODS: This review followed PRISMA guidelines and was prospectively registered in PROSPERO (CRD420251138158). Comprehensive searches were conducted in MEDLINE, PubMed, EMBASE, Registers, and the Cochrane Library through July 2025. Eligible studies included clinical trials and observational studies reporting visual, refractive, safety, or patient-reported outcomes of presbyopia-correcting pIOLs. Risk of bias was assessed using the Cochrane and ROBINS-I tools.
RESULTS: 6 studies (354 eyes) were included. Contemporary pIOL designs; EVO Viva Implantable Collamelar Lens, trifocal Implantable Phakic Contact Lens, and ArtiPlus achieved at least 75% of eyes within ±0.50 diopter of target refraction, and 80% to 90% of patients attained functional spectacle independence. Glare and halos were commonly reported but generally mild. No sight-threatening adverse events occurred during short-term follow-up.
CONCLUSIONS: Early evidence suggests favorable short-term safety and functional outcomes for presbyopia-correcting pIOLs while preserving the crystalline lens and residual accommodative function. However, evidence remains limited by short follow-up, small sample sizes, and industry sponsorship. Independent, long-term studies are required to establish their definitive role in refractive surgery.
REGISTRATION: PROSPERO CRD420251138158.